|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eguia E, Baker T and Baker M:
Hepatocellular carcinoma: Surgical management and evolving
therapies. Cancer Treat Res. 192:185–206. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang H and Li W: Recent update on
comprehensive therapy for advanced hepatocellular carcinoma. World
J Gastrointest Oncol. 13:845–855. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peng TR, Weng YF, Wu TW, Wu CC, Chou YC
and Hsu CS: Efficacy and safety of sorafenib or lenvatinib for
advanced hepatocellular carcinoma after failure of first-line
atezolizumab plus bevacizumab: A systematic review and
meta-analysis. Cancers (Basel). 16:28132024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luo X, He X, Zhang X, Zhao X, Zhang Y, Shi
Y and Hua S: Hepatocellular carcinoma: Signaling pathways, targeted
therapy, and immunotherapy. MedComm (2020). 5:e4742024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Childs A, Aidoo-Micah G, Maini MK and
Meyer T: Immunotherapy for hepatocellular carcinoma. JHEP Rep.
6:1011302024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang C, Kuo JC, Huang Y, Hu Y, Deng L,
Yung BC, Zhao X, Zhang Z, Pan J, Ma Y and Lee RJ: Optimized
liposomal delivery of bortezomib for advancing treatment of
multiple myeloma. Pharmaceutics. 15:26742023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wahl K, Siegemund M, Lehner F, Vondran F,
Nüssler A, Länger F, Krech T, Kontermann R, Manns MP,
Schulze-Osthoff K, et al: Increased apoptosis induction in
hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion
protein combined with bortezomib. Hepatology. 57:625–636. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alwahsh M, Farhat J, Talhouni S, Hamadneh
L and Hergenröder R: Bortezomib advanced mechanisms of action in
multiple myeloma, solid and liquid tumors along with its novel
therapeutic applications. EXCLI J. 22:146–168. 2023.PubMed/NCBI
|
|
10
|
Lara PN Jr, Longmate J, Reckamp K, Gitlitz
B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M,
et al: Randomized phase II trial of concurrent versus sequential
bortezomib plus docetaxel in advanced non-small-cell lung cancer: A
California cancer consortium trial. Clin Lung Cancer. 12:33–37.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ
and Cheng AL: Synergistic interactions between sorafenib and
bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt
inactivation. J Hepatol. 52:88–95. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Honma Y, Shimizu S, Takehara T and Harada
M: Sorafenib enhances proteasome inhibitor-induced cell death via
inactivation of Akt and stress-activated protein kinases. J
Gastroenterol. 49:517–526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tan CRC, Abdul-Majeed S, Cael B and Barta
SK: Clinical pharmacokinetics and pharmacodynamics of bortezomib.
Clin Pharmacokinet. 58:157–168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dimopoulos MA, Moreau P, Palumbo A, Joshua
D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, et
al: Carfilzomib and dexamethasone versus bortezomib and
dexamethasone for patients with relapsed or refractory multiple
myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre
study. Lancet Oncol. 17:27–38. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mansour MA, Aljoufi MA, Al-Hosaini K,
Al-Rikabi AC and Nagi MN: Possible role of selective, irreversible,
proteasome inhibitor (carfilzomib) in the treatment of rat
hepatocellular carcinoma. Chem Biol Interact. 215:17–24. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu B, Gao J, Shi J, Wen P, Guo W and Zhang
S: m6A reader YTHDF3 triggers the progression of
hepatocellular carcinoma through the YTHDF3/m6
A-EGFR/STAT3 axis and EMT. Mol Carcinog. 62:1599–1614. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang M, Qi F, Zhang K, Zhang X, Ma J, Xia
S, Chen L, Yu Z, Chen J and Chen D: MARCKSL1-2 reverses
docetaxel-resistance of lung adenocarcinoma cells by recruiting
SUZ12 to suppress HDAC1 and elevate miR-200b. Mol Cancer.
21:1502022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo D, Zhang M, Wei T, Zhang X, Shi X,
Tang H, Ding M, Li J, Zhang S and Guo W: NFKBIZ regulates NFκB
signaling pathway to mediate tumorigenesis and metastasis of
hepatocellular carcinoma by direct interaction with TRIM16. Cell
Mol Life Sci. 81:1672024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang F, Gao J, Liu X, Sun Y, Liu L, Hu B,
Wang Z, Shi J, Guo W and Zhang S: LATS-regulated
nuclear-cytoplasmic translocation of SREBP2 inhibits hepatocellular
carcinoma cell migration and invasion via epithelial-mesenchymal
transition. Mol Carcinog. 62:963–974. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ding L, Ren C, Yang L, Wu Z, Li F, Jiang
D, Zhu Y and Lu J: OSU-03012 disrupts Akt signaling and prevents
endometrial carcinoma progression in vitro and in vivo. Drug Des
Devel Ther. 15:1797–1810. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao J, Shi X, Sun Y, Liu X, Zhang F, Shi
C, Yu X, Yan Z, Liu L, Yu S, et al: Deficiency of
betaine-homocysteine methyltransferase activates
glucose-6-phosphate dehydrogenase (G6PD) by decreasing arginine
methylation of G6PD in hepatocellular carcinogenesis. Sci China
Life Sci. 67:1648–1665. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roberts A, Trapnell C, Donaghey J, Rinn JL
and Pachter L: Improving RNA-Seq expression estimates by correcting
for fragment bias. Genome Biol. 12:R222011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen S, Zhou Y, Chen Y and Gu J: fastp: An
ultra-fast all-in-one FASTQ preprocessor. Bioinformatics.
34:i884–i890. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo N, Xia Y, He N, Cheng H, Zhang L and
Liu J: IRGM deficiency exacerbates sepsis-induced acute lung injury
by inhibiting autophagy through the AKT/mTOR signaling pathway. J
Inflamm Res. 17:10255–10272. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Kuang J, Li XT, Hu X, Liu YH, Hu
CP, Wang M, Wang Q and Zhang Z: Dimethyl fumarate is repurposed to
ameliorate aortic aneurysm and dissection in mice. Eur J Pharmacol.
988:1772152025. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu Q, Zhang J, Li J, Song Y, Pan J, Mei C,
Cui M, He Q, Wang H, Li H, et al: Sirtuin 5-mediated
desuccinylation of ALDH2 alleviates mitochondrial oxidative stress
following acetaminophen-induced acute liver injury. Adv Sci
(Weinh). 11:e24027102024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Menyhárt O, Nagy Á and Győrffy B:
Determining consistent prognostic biomarkers of overall survival
and vascular invasion in hepatocellular carcinoma. R Soc Open Sci.
5:1810062018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Győrffy B: Integrated analysis of public
datasets for the discovery and validation of survival-associated
genes in solid tumors. Innovation (Camb). 5:1006252024.PubMed/NCBI
|
|
30
|
Lin Y, Zhong W, Lin Q, Ye Y, Li S, Chen H,
Liu H, Xu L, Zhuang W, Chen S, et al: SFPQ promotes the
proliferation, migration and invasion of hepatocellular carcinoma
cells and is associated with poor prognosis. Am J Cancer Res.
13:2269–2284. 2023.PubMed/NCBI
|
|
31
|
Oshima J and Campisi J: Fundamentals of
cell proliferation: Control of the cell cycle. J Dairy Sci.
74:2778–2787. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Deng Y, Li Y, Yang M, Gao Y, Luo X, Chen
H, Guo M, Yang X, Liu Y, He J, et al: Carfilzomib activates ER
stress and JNK/p38 MAPK signaling to promote apoptosis in
hepatocellular carcinoma cells. Acta Biochim Biophys Sin
(Shanghai). 56:697–708. 2024.PubMed/NCBI
|
|
34
|
Tang W, Chen Z, Zhang W, Cheng Y, Zhang B,
Wu F, Wang Q, Wang S, Rong D, Reiter FP, et al: The mechanisms of
sorafenib resistance in hepatocellular carcinoma: Theoretical basis
and therapeutic aspects. Signal Transduct Target Ther. 5:872020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lv Z, Liu L, You J, Zhou P, Su Y, Zhao K,
Zhang J and Zhu F: Small HBV surface antigen drives regorafenib
resistance in HCC via KIAA1429-dependent m6A modification of CCR9.
J Med Virol. 96:e298942024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Leowattana W, Leowattana T and Leowattana
P: Systemic treatment for unresectable hepatocellular carcinoma.
World J Gastroenterol. 29:1551–1568. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Arnold SM, Chansky K, Leggas M, Thompson
MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G and
Baggstrom MQ: Phase 1b trial of proteasome inhibitor carfilzomib
with irinotecan in lung cancer and other irinotecan-sensitive
malignancies that have progressed on prior therapy (Onyx IST
reference number: CAR-IST-553). Invest New Drugs. 35:608–615. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu H, Li L, Ai Z, Yin J and Chen L:
Pristimerin induces apoptosis of oral squamous cell carcinoma cells
via G1 phase arrest and MAPK/Erk1/2 and Akt signaling
inhibition. Oncol Lett. 17:3017–3025. 2019.PubMed/NCBI
|
|
39
|
Wang B, Li R, Wu S, Liu X, Ren J, Li J, Bi
K, Wang Y and Jia H: Breast cancer resistance to cyclin-dependent
kinases 4/6 inhibitors: Intricacy of the molecular mechanisms.
Front Oncol. 11:6515412021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Desvoyes B and Gutierrez C: Roles of plant
retinoblastoma protein: Cell cycle and beyond. EMBO J.
39:e1058022020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Humayun A and Fornace AJ Jr: GADD45 in
stress signaling, cell cycle control, and apoptosis. Adv Exp Med
Biol. 1360:1–22. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Palomer X, Salvador JM, Griñán-Ferré C,
Barroso E, Pallàs M and Vázquez-Carrera M: GADD45A: With or without
you. Med Res Rev. 44:1375–1403. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li Y, Qian H, Li X, Wang H, Yu J, Liu Y,
Zhang X, Liang X, Fu M, Zhan Q and Lin C: Adenoviral-mediated gene
transfer of Gadd45a results in suppression by inducing apoptosis
and cell cycle arrest in pancreatic cancer cell. J Gene Med.
11:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang M, Tian B, Shen J, Xu S, Liu C, Guan
L, Guo M and Dou J: Bavachin induces apoptosis in colorectal cancer
cells through Gadd45a via the MAPK signaling pathway. Chin J Nat
Med. 21:36–46. 2023.PubMed/NCBI
|
|
46
|
Wang Y, Gao H, Cao X, Li Z, Kuang Y, Ji Y
and Li Y: Role of GADD45A in myocardial ischemia/reperfusion
through mediation of the JNK/p38 MAPK and STAT3/VEGF pathways. Int
J Mol Med. 50:1442022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang HH, Chang TY, Lin WC, Wei KC and Shin
JW: GADD45A plays a protective role against temozolomide treatment
in glioblastoma cells. Sci Rep. 7:88142017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Peretz G, Bakhrat A and Abdu U: Expression
of the Drosophila melanogaster GADD45 homolog (CG11086) affects egg
asymmetric development that is mediated by the c-Jun N-terminal
kinase pathway. Genetics. 177:1691–1702. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Geifman-Holtzman O, Xiong Y and Holtzman
EJ: Gadd45 stress sensors in preeclampsia. Adv Exp Med Biol.
793:121–129. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hildesheim J, Bulavin DV, Anver MR, Alvord
WG, Hollander MC, Vardanian L and Fornace AJ Jr: Gadd45a protects
against UV irradiation-induced skin tumors, and promotes apoptosis
and stress signaling via MAPK and p53. Cancer Res. 62:7305–7315.
2002.PubMed/NCBI
|
|
51
|
Yang P, Wen H, Zhong T, Hu H, Zhu B, Xia
K, Xu M and Bian M: GADD45α is involved in the apoptosis of
lymphocytes induced by riboflavin and ultraviolet light.
Transfusion. 57:646–656. 2017. View Article : Google Scholar : PubMed/NCBI
|
